Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Merloni

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Recenti Progressi in Medicina|June 16, 2026
Filippo Merloni
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenaseFilippo Merloni, Nicoletta Ranallo, Laura Scortichini, et al.
Cancers|February 11, 2023
Current State and Future Challenges for PI3K Inhibitors in Cancer TherapyMarianna Sirico, Alberto D'Angelo, Caterina Gianni, et al.
JCO Global Oncology|July 8, 2020
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 PandemicZelmira Ballatore, Lucia Bastianelli, Filippo Merloni, et al.
Molecular and Clinical Oncology|February 2, 2018
Long-responders to anti-HER2 therapies: A case report and review of the literatureLuca Cantini, Mirco Pistelli, Agnese Savini, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLCLuca Cantini, Federica Pecci, Filippo Merloni, et al.
Journal of Oncology|May 31, 2021
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution ExperienceMirco Pistelli, Filippo Merloni, Sonia Crocetti, et al.
Biomedicines|October 26, 2024
A Novel <i>AKT1</i>, <i>ERBB2</i>, <i>ESR1</i>, <i>KRAS</i>, <i>PIK3CA</i>, and <i>TP53</i> NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 InhibitorsAlessandra Virga, Caterina Gianni, Michela Palleschi, et al.
International Journal of Molecular Sciences|November 26, 2022
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast CancerCaterina Gianni, Michela Palleschi, Filippo Merloni, et al.
Critical Reviews in Oncology/Hematology|May 17, 2020
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysisLuca Cantini, Filippo Merloni, Silvia Rinaldi, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Recenti Progressi in Medicina|June 16, 2026
Filippo Merloni
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenaseFilippo Merloni, Nicoletta Ranallo, Laura Scortichini, et al.
Cancers|February 11, 2023
Current State and Future Challenges for PI3K Inhibitors in Cancer TherapyMarianna Sirico, Alberto D'Angelo, Caterina Gianni, et al.
JCO Global Oncology|July 8, 2020
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 PandemicZelmira Ballatore, Lucia Bastianelli, Filippo Merloni, et al.
Molecular and Clinical Oncology|February 2, 2018
Long-responders to anti-HER2 therapies: A case report and review of the literatureLuca Cantini, Mirco Pistelli, Agnese Savini, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLCLuca Cantini, Federica Pecci, Filippo Merloni, et al.
Journal of Oncology|May 31, 2021
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution ExperienceMirco Pistelli, Filippo Merloni, Sonia Crocetti, et al.
Biomedicines|October 26, 2024
A Novel <i>AKT1</i>, <i>ERBB2</i>, <i>ESR1</i>, <i>KRAS</i>, <i>PIK3CA</i>, and <i>TP53</i> NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 InhibitorsAlessandra Virga, Caterina Gianni, Michela Palleschi, et al.
International Journal of Molecular Sciences|November 26, 2022
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast CancerCaterina Gianni, Michela Palleschi, Filippo Merloni, et al.
Critical Reviews in Oncology/Hematology|May 17, 2020
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysisLuca Cantini, Filippo Merloni, Silvia Rinaldi, et al.
Pageof 3